57th ASH Annual Meeting and Exposition (December 5-8, 2015): 621. Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

Hodgkin Lymphoma: Biology, excluding Therapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma

Ralph Schwiebert, MBBS¹^*, Sharon Barrans, PhD²^*, Jan Taylor³^*, Andrew S Jack¹ and Cathy H Burton¹^*

¹HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
²St James Institute of Oncology, HMDS, Leeds, United Kingdom
³HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

1438

Multiparametric Analysis of Intra-Tumoral T-Cells in Hodgkin's Lymphoma Using Mass Cytometry (CyTOF)

Jose Villasboas Bisneto, M.D.¹ and Stephen M Ansell, M.D., Ph.D.²

¹Division of Hematology - Department of Medicine, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN

1439

Mutations in CD58 and Other Immune System Related Genes in Hodgkin Lymphoma

Fazlyn Reeny Abdul Razak^*, Arjan Diepstra, MD, PhD, Lydia Visser, PhD^* and Anke Van den Berg, PhD

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

1440

Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity

Christopher Daniel Carey, M.D.,¹^*, Courtney Connelly²^*, Evisa Gjini, PhD¹, Margaretha GM Roemer, MS²^*, Edward Stack, PhD³^*, Stephen Hodi, MD²^*, Margaret A. Shipp, MD² and Scott J. Rodig, M.D., Ph.D.⁴

¹Department of Pathology, Brigham & Women's Hospital, Boston, MA
²Dana-Farber Cancer Institute, Boston, MA
³PerkinElmer, Hopkington, MA
⁴Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

1441

Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL

Tarsheen K. Sethi, MD, MS¹, Van T Nguyen, MD²^*, Shaoying Li, MD³^*, David S Morgan, MD⁴, John P. Greer, MD⁴ and Nishitha M Reddy, M.B.B.S.⁴

¹Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
³Department of Hematopathology, MD Anderson Cancer Center, Houston, TX
⁴Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

1442

Clinical Impact of CD8+ Cells in Hodgkin Lymphoma Lymphadenopaties. Contribution of Flow Cytometry

Sara Alonso, MD¹^*, Maria Belen Vidriales, MD, PhD¹^*, Maria Dolores Caballero, MD, PhD²^*, Oscar Blanco³^*, J Galende⁴^*, Maria Jesús Peñarrubia, MD, PhD⁵^*, Esther Zato⁵^*, Abelardo Barez⁶^*, Julio Davila⁶^*, Juan Carlos Caballero, MD⁷^*, Alberto Orfao, MD, PhD⁸, Marcos González, MD, PhD⁹^* and Ramon Garcia-Sanz, MD, PhD¹⁰^*

¹Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
²Universitiy Hospital of Salamanca, Universitiy Hospital of Salamanca, Salamanca, Spain
³Pathology Department, University Hospital of Salamanca, Salamanca, Spain
⁴Virgen del Bierzo Hospital, Ponferrada, Spain
⁵Clinical Hospital of Valladolid, Valladolid, Spain
⁶University Hospital of Salamanca, Salamanca, Spain
⁷Hematology, Salamanca Universitary Hospital, Salamanca, Spain
⁸Centro de Investigación del Cáncer (CIC, IBMCC USAL-CSIC), Servicio General de Citometría, Universidad de Salamanca, Salamanca, Spain
⁹Hospital Clínico Universitario de Salamanca, Salamanca, Spain
¹⁰Hematology Service, University Hospital of Salamanca, Salamanca, Spain

See more of: Hodgkin Lymphoma: Biology, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

621.P1.23 621. Hodgkin Lymphoma: Biology, excluding Therapy: Poster I